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ABSTRACT
In Australia, pneumococcal vaccine is provided free to all adults aged ≥65 years and Indigenous people
aged 15–65 years, and is subsidized for non-Indigenous adults <65 years of age with risk factors. This
study aimed to explore pneumococcal vaccination uptake in older patients attending 550 Australian
general practices from 2010–2017 by patient sociodemographics, presence of comorbidities and prac-
tice characteristics. Study 1: a cross-sectional analysis of ‘active’ patients aged ≥65 years in each year was
performed to calculate annual pneumococcal vaccination uptake. Study 2: a cohort of 58,589 ‘every year’
patients aged 60–65 years in 2010 was analyzed to identify the number of patients immunized during
the study period. Logistic regression models assessed associations between vaccination, patient and
practice characteristics. Annual pneumococcal vaccine uptake varied by patient’s age (65–74 or
≥75 years), presence of comorbidities and regularity of practice visits (range 36% to 76%), and it
declined slowly from 2011–2016 amongst all groups. Cohort analyses showed that 69% of those aged
60–65 years in 2010 had a recorded pneumococcal vaccination by 2017 (peak age of vaccina-
tion = 66 years), and vaccination was more likely among those with comorbidities, ex-smokers and
frequent attenders to practices. Findings demonstrate that the NPS MedicineInsight database provides
estimates of vaccination uptake consistent with past surveys, reproducible every year and at low cost. It
has the advantage of additional clinical information compared to the Australian Immunization Register.
Whilst vaccination uptake was adequate among ‘every year’ patients, interventions are needed to
improve pneumococcal vaccination for all older Australians.
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Invasive pneumococcal disease, caused by different ser-
ogroups of the bacteria Streptococcus pneumoniae, is an
important contributor to morbidity and mortality worldwide.
Severe forms of the disease (i.e. pneumonia, meningitis and
septicemia) are more prevalent in infants, the elderly, and
among those with impaired immune systems.1–3
Vaccination is an essential element of the global effort to
prevent pneumococcal disease and understanding gaps in vac-
cination uptake is essential when trying to improve rates.1,4 In
Australia, pneumococcal polysaccharide vaccine (PPV) is pro-
vided free to all adults aged 65 years and over, and Indigenous
people aged 15–65 years as part of the Australian Immunisation
Programs (AIP)5 and is subsidized under the Pharmaceutical
Benefits Schedule (PBS) for non-Indigenous adults < 65 years of
age with comorbidities.6 For non-Indigenous adults without
comorbidities, a single dose of the PPV is recommended at
65 years of age, and for those aged > 65 years who did not
receive a dose when turning 65 years, a single catch-up dose of
PPV should be offered as soon as possible. For Indigenous
adults, a first dose is recommended when reaching the age of
50 years. Routine revaccination with PPV is recommended only
for Indigenous adults or those with comorbidities. In these cases
up to 3 doses (i.e. 2 revaccinations) of PPV in adulthood are
recommended depending on the risk factors.6
Although in late 2016 the Australian Immunization
Register (AIR) was extended to include data on all vaccina-
tions performed in adults,7 under-reporting of vaccines given
in general practice is believed to be occurring.8 To date, no
report on pneumococcal vaccination has been undertaken
using AIR data.7 In the past, vaccination uptake in Australia
has been estimated using intermittent community surveys,
which have limitations such as high cost and self-reported
data.9,10 A systematic review of Australian studies from
1992–2013, estimated that pneumococcal vaccination cover-
age for people ≥65 years ranged from 50.3% to 72.8% after the
introduction of free vaccine,9 similar to the 54% found in the
national immunization survey.10 However, all available data is
derived from cross-sectional studies, most of them in specific
groups, and with limited data on sociodemographic features
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or other patient characteristics which may be associated with
vaccination uptake.
Given that the vast majority of all child NIP vaccines5,11 and
vaccinations for those aged ≥65 years10,12 are delivered through
general practice in Australia,12 using electronic health records
(EHR) from a longitudinal general practice database may have
some advantages.13 In 2015 the National Prescribing Service
(NPS) MedicineWise made available the MedicineInsight plat-
form for research purposes.14 With data from EHR collected
since 2010 from approximately 650 general practices and
four million patients, it is a rich source of information about
the use of medicines,15 clinical investigations,16 chronic
diseases17 and vaccinations.18 Using MedicineInsight dataset
we sought a contemporary, verifiable, estimate for annual pneu-
mococcal vaccination uptake (Study 1, time series analysis), and
explore sociodemographic characteristics, underlying medical
conditions, consultation attendance and practice characteristics
associated with uptake when, according to their age, patients
become eligible for the free vaccination scheme,5 in order to
identify the potential for improvement in vaccine delivery (Study
2, retrospective cohort analysis). Additionally, we sought evi-
dence about a strategy that has been promoted of using patients’
attendance for their annual influenza vaccination as an oppor-
tunity to administer the pnenumococcal vaccine.
Patients and methods
Data source
For both studies we used data from the NPS MedicineInsight,
a general practice database developed and managed by NPS
MedicineWise.19 De-identified EHR data is extracted from
participating general practices around Australia, varying by
size, billing methods, and range and type of services offered.
All patients receive a unique identifying number within
a practice, so each patient is connected to the same practice
throughout the period of data extraction. This generates
a large, longitudinal database, with patients of all ages, from
all States and geographic regions.
Sample
Study 1 (time series analysis) aimed to investigate annual pneu-
mococcal vaccination uptake from 2010 to 2016 (i.e. the per-
centage of patients ever vaccinated) among all ‘active’ patients
attending the practice that year and aged ≥ 65 years. ‘Active’
patients were defined according to the Royal Australian College
of General Practitioners as any person who had at least three
consultations at the practice in two consecutive years.20 We also
analyzed the proportion of ‘active’ patients aged ≥65 years who
received the first pneumococcal vaccination each year.
Study 2 (retrospective cohort analysis) aimed to investigate
factors associated with the uptake of pneumococcal vaccination
(i.e. first recorded dose) when, according to their age, patients
became eligible for the free vaccination scheme.5 The cohort
sample included all patients aged between 60 and 65 years in
2010, who had at least one consultation in every year from 2010
to 2017 (identified as ‘every year’ patients in this study). The
same cohort sample was used to analyze the administration of
a pneumococcal and an influenza vaccine on the same day in
2017 (for those who had not received pneumococcal vaccina-
tion until 2016).
Data extraction
A data extraction algorithm was used to identify pneumococ-
cal vaccines in the dataset for both studies (i.e. time series and
retrospective cohort analysis), which contained all immuniza-
tions recorded between 2010 and 2017. Administration of
a vaccine can be recorded by GPs and practice nurses from
either a drop down menu or as free text.19 For that reason,
pneumococcal vaccination was identified by the vaccine brand
names (Pneumovax® or Prevenar 13®) and also by combining
the terms ‘pneumo’ and ‘vax’, ‘vacc’ or ‘injection’, as well as
synonyms or possible misspelling of these terms. We also
searched the dataset for records of pneumococcal vaccine
administered before 2010, because previous studies have
shown that many practices in the MedicineInsight database
have EHR going back to 2000.15,17
Moreover, to assess the proportion of the cohort who had
not received the pneumococcal vaccine until 2016 but were
vaccinated against pneumococcal and influenza on the
same day in 2017 (second part of Study 2), information on
influenza vaccination was also obtained using a similar data
extraction algorithm. The immunization field was searched
for the term ‘flu’ or brand names of this vaccine (i.e. Afluria®,
Agrippal®, Fluad®, Fluarix, FluQuadri™, Influvac®, Vaxigrip®).
Outcomes
In Study 1, annual pneumococcal vaccination uptake for the
period 2010–2016 was estimated as the proportion of ‘active’
patients attending the practice that year and aged ≥ 65 years
who received the vaccine. Two different frequency measures
were estimated: 1) ‘ever vaccinated’, defined as the proportion
of ‘active’ patients who, according to the EHR, received at
least one dose of pneumococcal vaccine between 2000 and the
correspondent year, and 2) ‘vaccinated that year’, defined as
the proportion of ‘active’ patients who were vaccinated against
pneumococcal in that year and had no previous vaccination
identified in the EHR.
In Study 2, pneumococcal vaccination rate was defined as
the proportion of ‘every year’ patients (at least one annual
consultation between 2010 and 2017) who were aged
60–65 years in 2010 who received their first dose of the
vaccine (i.e. no previous adult vaccination).We also estimated
the proportion of patients who received pneumococcal and
influenza vaccines at the same visit in 2017, among those who
had not received pneumococcal vaccine until 2016.
Covariates
For patients, covariates included gender, Indigenous status
(Aboriginal and/or Torres Strait Islander: yes/no), patient's
Index of Relative Socio-economic Advantage and
Disadvantage (IRSAD) quintile and comorbidity. IRSAD is
a macroeconomic indicator of relative economic and social
advantage/disadvantage position within an area/postcode
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compared to the rest of the country.21 Chronic conditions that
can lead to an increased risk of invasive pneumococcal dis-
ease, as listed in the Australian Immunisation Handbook,6
were extracted from MedicineInsight (diagnosis or reason
for encounter) using algorithms from a previous study.17
These included: cardiac disease, chronic respiratory or neuro-
logical conditions, immunocompromising conditions (e.g.
those with malignancy or HIV infection), chronic liver dis-
ease, diabetes mellitus, chronic renal failure and
hemoglobinopathies.6 Individuals with at least one of these
conditions were considered as having comorbidity. Covariates
for general practices included: state, rurality (classified as
major cities; inner regional; outer regional/remote/very
remote), and the practice IRSAD quintiles.
The median number of visits per year to the practice was
also included as a covariate. Duplicate entries for the same
patient on the same date were excluded.
Statistical analysis
For Study 1, annual pneumococcal vaccination uptake esti-
mates from 2010 to 2016 among ‘active’ patients aged
≥65 years were presented graphically, including: 1) the pro-
portion of patients who were ‘ever vaccinated’ between 2000
and the correspondent year and 2) the proportion of patients
‘vaccinated that year’ (i.e. no previous pneumococcal vaccina-
tion in the EHR).
In Study 2, the association between pneumococcal vaccina-
tion and practice or patient’s characteristics among a cohort
of individuals aged 60–65 years in 2010 was assessed using
logistic regression with robust standard errors for taking into
account clustering within the practice. Practice characteristics
were mutually adjusted, while patient variables were adjusted
for practice characteristics, gender, and median number of
consultations per year. Results are presented as adjusted pro-
portions. All analyses were performed in the statistical soft-
ware Stata 15.0 (StataCorp, Texas, USA). The Human
Research Ethics Committee of the University of Adelaide
exempted this study from ethical review because it used exist-
ing and non-identifiable data.
Results
Study 1 shows that population sample size of ‘active’ patients
aged ≥ 65 years (mean: 68.3, SD: 8.1) for the time series
analysis varied by year (2010: 220,801, 2011: 257,737, 2012:
300,581, 2013: 348,845, 2014: 400,056, 2015: 456,184, 2016:
470,034, 2017: 453,215). The pneumococcal vaccination
uptake (i.e. ‘ever vaccinated’) in each calendar year from
2010 to 2016 was 63%, 60%, 56%, 54%, 53%, 52% and 52%,
respectively (Figure 1). It varied between 36% to 76%,
depending on the patient’s age and presence of comorbidities,
and in general decreased over time in all groups (p < .001).
The lowest rate was observed among those aged 65–74 years
without comorbidity, and the highest among those aged
≥75 years with comorbidities. Moreover, the decrease in
pneumococcal vaccination uptake in patients without comor-
bidities was more pronounced (p < .001).
Figure 1 also shows the proportion of elderly individuals
‘vaccinated that year’. In 2016 it varied from 3% to 15%. The
highest rate was for those aged 65–74 years with a comorbid-
ity, while those aged ≥ 75 years were less likely to be immu-
nized, independent of having or not comorbidity.
Figure 2 shows the pneumococcal vaccination rate for
patients aged 60–65 years in 2010 (Study 2, cohort analysis).
Of the 259,236 eligible patients, 58,549 (22.6%) had at least
one annual consultation between 2010 and 2017 (‘every year’
patients). This cohort of ‘every year’ patients had similar sex
and IRSAD distribution compared to all individuals aged
60–65 years in the database (see Supplementary Table 1).
The cumulative incidence of vaccination uptake by the end
of 2017 among ‘every year’ patients was 69% (n = 40,160).
Approximately 80% of those ‘every year’, vaccinated, patients
received their first dose after they turned 65 years, with a peak at
Figure 1. Pneumococcal vaccine uptake in each year among ‘active’ patients aged ≥ 65 years that year. Results from the time series analysis (Study 1).
Australia, 2010–2016.
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66 years (Figure 3). The same figure also shows that before the
age of 65 years, those receiving the pneumococcal vaccine were
up to five times more likely to have a comorbidity.
Table 1 shows pneumococcal vaccine uptake among
‘every year’ patients was 5% lower among practices located
in outer/remote/very remote areas compared to inner regional
or major cities and 10% lower in the second highest IRSAD
quintile areas (65. and 4%) compared to the lowest quintile
(71.7%). Small differences were observed according to gender
or patient’s IRSAD, while uptake was highest among those
with comorbidities (71.8%) or ex-smokers (71.2%).
Among ‘every year’ patients who had never received
a pneumococcal vaccine up to 2016 (n = 22,120), we examined
the pattern of immunization in 2017 (Figure 4). Of the 3,731
pneumococcal vaccinations in that year, 87% (n = 3,244) were
given between March and August, coinciding with the peak of
influenza vaccinations. Overall, 53% (n = 1,980) of those receiv-
ing the pneumococcal vaccine in 2017 were also immunized
against influenza on the same day, while 10,205 eligible patients
only received the influenza vaccine, and 8,184 did not receive
any immunization during that year.
Discussion
The proportion of older Australians (aged 65–74 years or
≥ 75 years) with or without comorbidities, immunized
against pneumococcus, declined slowly from 2010 (range
76%-48%) to 2017 (range 69%-39%). However, the number
of vaccinations given each year remained relatively stable.
Figure 2. Flowchart of the selection of patients included in the cohort sample (Study 2) with respective pneumococcal vaccination rates. Australia, 2010–2017.
Figure 3. Age of first pneumococcal vaccination among ’every year’ patients aged 60–65 years in 2010 (at least one consultation per year from 2010 to 2017) with
and without comorbidities. Results from cohort data analysis (Study 2). Australia, 2010–2017.
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Vaccination uptake was higher in patients with comorbidities
and those aged ≥75 years, and most patients were immunized
in the years immediately after they turn 65 years, which
coincides with free access to the vaccine under the NIP.5
Whilst pneumococcal vaccination uptake varied slightly
according to practice and patient characteristics, only the
presence of comorbidities or being an ex-smoker affected
rates appreciably. Finally, as expected, there is evidence of co-
administration of seasonal influenza and pneumococcal vac-
cination and this knowledge could inform strategies and
guide the allocation of resources to increase vaccination
rates. In fact, the concept of ‘make mine a double’, combining
influenza and pneumococcal vaccination, may be useful in
encouraging higher uptake of the latter.
The finding that pneumococcal vaccination uptake among
those aged ≥75 years with comorbidities declined, albeit
slowly, is of concern. This decline is consistent with data
from the New South Wales Health Survey22 and may be
related to publicity about severe injection site reactions in
2011 and the subsequent removal of the recommendation of
revaccination after 5 years in people without a medical risk
factor. For patients with preexisting conditions, however, up
to two additional doses are still indicated, depending on the
medical history and age.5
Results of the cohort sample demonstrated that vaccination
uptake might be linked to how often people visit different
practices to obtain care, since Australians are not registered
with one practice. Higher uptake in those we labeled
‘every year’ compared to ‘not every year’ patients suggest
that being associated with one general practice and therefore
having more opportunities for vaccination might play a role.
Supporting this idea, the vaccination uptake among
‘every year’ patients (69%) was similar to that found among
patients aged 65 years or over in England (70%), where
patients are registered with only one practice.23 A previous
Australian study found a pneumococcal vaccination uptake of
73%, slightly higher than ours, but data was obtained from
health provider forms (BEACH study).24 In the cohort,
patients who were intermittent or infrequent attenders at
a practice (‘not every year’ patients) may be receiving care
Table 1. Pneumococcal vaccination ratesa among ’every year‘ patients aged
60–65 years in 2010 (at least one consultation per year from 2010 to 2017),
according to patient and practice’s characteristics. Results from cohort data





vaccinated (%, 95%CI) p-value
Practice’s Characteristics
Rurality < 0.0001
Major cities 56.2 68.5 (68.0;69.1)




IRSAD Quintile < 0.0001
Very high 11.7 69.8 (68.7;71.0)
High 27.2 65.4 (64.6;66.2)
Middle 19.9 68.7 (67.8;69.6)
Low 21.0 68.9 (68.1;69.7)
Very Low 20.2 71.7 (70.8;72.5)
Patient’s Characteristics
Gender 0.0051
Male 43.5 68.0 (67.4;68.6)
Female 56.5 69.1 (68.6;69.6)
IRSAD quintile 0.1444
Very high 22.0 67.7 (66.5;68.9)
High 16.2 67.7 (66.7;68.8)
Middle 24.1 69.4 (68.5;70.3)
Low 17.9 68.9 (68.0;69.9)
Very Low 19.8 69.1 (68.0;70.2)
Comorbiditiesb < 0.0001
No 42.6 64.4 (63.8;65.0)
Yes 57.4 71.8 (71.3;72.3)
Smoking status < 0.0001
Non smoker 53.5 68.2 (67.7;68.7)
Smoker 6.9 64.9 (63.4;66.3)
Ex smoker 35.6 71.2 (70.6;71.8)
Not recorded 4.1 57.4 (55.4;59.4)
aAnalyses of practice’s characteristics are adjusted for each other and median
yearly consultations; analyses of patient’s characteristics are adjusted for
gender, practice’s characteristics and median yearly consultations.
bComorbidities include: cardiac disease, chronic neurological disease, chronic
respiratory disease, chronic liver disease, immunocompromising conditions or
other chronic diseases (including chronic renal failure, diabetes mellitus or
hemoglobinopathies).
Figure 4. Total number of pneumococcal and influenza immunizations among ‘every year’ patients aged 60–65 years in 2010 (at least one consultation per year from
2010 to 2016), among those consulting in 2017 and without a previous record of a pneumococcal vaccine (N = 22,120). Results from cohort data analysis (Study 2).
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from another practice, including pneumococcal vaccination,
which is not recorded at their MedicineInsight practice, lead-
ing to lower pneumococcal uptake estimates.
We found that most pneumococcal vaccinations are given
at or just after the age of 65 years. This may indicate a high
level of awareness about the NIP, probably influenced by
repeated prompts that appear on the GPs screen at every
consultation once the patient turns 65 years (generated auto-
matically by the installed medical software programs and
based on the EHR), informing about the availability of (free)
pneumococcal vaccination and its importance. The higher
uptake in those with comorbidities also suggests that the
message about who is at higher risk is reasonably well
known, with many of these patients getting vaccinated before
the age of 65 years. Understanding why many are either not
offered, delay acceptance or refuse pneumococcal vaccination
is more difficult to explain, especially in the context of high
influenza vaccination uptake in those aged 65 years or over.
Authors of a review on vaccine hesitancy suggest that social,
religious, political, cultural and emotional factors play a role
and these are influenced by changes in scientific, cultural and
medico-legal environments, in addition to vaccine policies,
health professional, media and communication.25 A National
Immunization Survey undertaken in 2016 found that a third
of Australians aged 70 years or over do not think they need to
be immunized against influenza, pneumonia, shingles or
whooping cough.26,13 Moreover, the BEACH study showed
that among 331 unvaccinated patients at risk of pneumococ-
cus infection (42% of those investigated in that study), 46%
were considered not at risk by the GP and 39% had a recorded
vaccine objection.24
Our results demonstrate the potential of MedicineInsight
data to monitor vaccination uptake, especially because such
data is potentially available on a weekly basis, results are
consistent with previous surveys, and the dataset provides
medical history and socioeconomic information from patients
and practices. We found that pneumococcal vaccination does
not vary appreciably by most practice and patient character-
istics, although having comorbidity or being an ex-smoker
increased rates. This contrasts with findings that the use of
medications15,27 or tests16 in Australia can vary with socio-
demographic factors, but it is similar to findings for influenza
vaccination uptake in general practice.18 Being available free
(after turning 65 years), easily accessible through general
practice and able to be offered opportunistically – for instance
at the time of influenza vaccination – makes it available to
everyone. In European countries, being an immigrant, living
alone or in rural areas, and being unmarried have been
associated with lower uptake of pneumococcal vaccination.28
This study has some limitations. First, the records
extracted and used in the analysis are entered and main-
tained for clinical purposes. Therefore, the quality and accu-
racy may vary by clinician or practice. For instance, the
information can be recorded as free text instead of using
standardized medical codes. However, to increase data qual-
ity algorithms used for data extraction included not only
medical codes, but also a combination of terms related to
pneumococcus vaccination as well as possible misspelling of
these terms.29 Second, Australians do not have to register
with a single practice. They can seek care from different
practices and may have received pneumococcal vaccination
or other medical care at another practice, hospital or clinic. It
is possible that the information does get recorded in the
MedicineInsight practice but only if the GP has asked
about and entered that information. This is probably more
likely to occur for ‘every year’ patients and this may account
for some of the differences found in our results. Third, we
cannot rule out double-counting of patients who visit more
than one MedicineInsight practice, but estimates suggest the
likelihood of this is low given the broad distribution of
MedicineInsight practices across geographic areas.19 Fourth,
our study cannot account for patients who refuse pneumo-
coccal vaccination, because the EHR used by Australian GPs
do not provide any structured way to record this, but
a previous study reported a rate of 7%.24 This will influence
the feasibility of attaining higher vaccination rates, but
should be balanced against reports that provider recommen-
dation is the most influential factor in a patient’s decision to
vaccinate.10 Lastly, our population is likely to be biased
toward patients who frequently attend a single practice and
therefore may not be fully representative of all older
Australians.
Despite these limitations, this study has several strengths:
the large number of patients, practices and GPs included
(with numbers increasing over time, but maintaining the
same distribution14), linkage of vaccination data with clin-
ical, sociodemographic and practice information, the addi-
tion of influenza vaccination data and the ability to create
a longitudinal cohort. Also, our results demonstrated that
estimates for vaccine uptake vary by how a ‘patient’ is
defined, and this has important ramifications for the inter-
pretation of any primary care data. In the future, the
Australian Immunization Register may also provide reliable
estimates, but currently MedicineInsight appears to be an
important data source, which can be used to provide esti-
mates of vaccination uptake that is reproducible every year,
has a low cost, with results consistent with past surveys.
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